Retrophin appoints board member
This article was originally published in Scrip
Retrophin, a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of rare diseases, has named Jeffrey A Meckler to its board of directors as a fourth independent director. Mr Meckler is currently a director of QLT an ultra-orphan ophthalmic biotechnology company based in Canada, as well as the managing director of The Andra Group, a life sciences consulting firm.
You may also be interested in...
The stereotypical view of an Alzheimer’s patient as an elderly person needs to change and interventions made earlier in the disease course, while we wait for novel drug therapies, said experts at a recent virtual meeting.
A steady flow of venture capital into the medical device industry continued in the first half of 2020 despite the novel coronavirus pandemic. While Biopharma companies secured more than $7.5bn in private financings between January and June.
Experts discuss the future of brain health, changing the stereotypical view of an Alzheimer’s patient and how technology and science have evolved the treatment possibilities for dementia patients in 2020 – even if ‘clinical practice is taking a long time to catch up.’